Clinician answer page

AYA survivorship transition: the clinician hand-off guide

Transfer from pediatric to adult care is where surveillance most often stops. This page gives the age-by-age plan, the contents of a hand-off letter an adult clinician can act on, and the reason cardio-oncology sits at the center of it.

Why transition failure is a cardio-oncology problem

Cardiac exposure travels with the survivor, the record does not

Cumulative anthracycline dose and radiation field detail are the two facts adult clinicians most often cannot obtain. If they are not written on a document the survivor holds, echo intervals get set by guesswork or dropped entirely.

The highest-risk window is the one with the least contact

Late cardiac and endocrine effects rise through the twenties and thirties, exactly when survivors change insurers, cities, and clinicians most often. Transition failure and late-effect onset overlap.

Adult clinicians inherit a schedule with no rationale

A hand-off letter that lists tests without the exposures behind them cannot be adapted. Give the exposure, the threshold, and the interval together so the receiving clinician can reason from it.

Autonomy is a clinical intervention, not a courtesy

Survivors who can state their own exposure history keep surveillance going. Building that skill from early adolescence is the single most portable protection you can give.

An age-by-age transition plan

Ages 12 to 14 — start naming the diagnosis

The adolescent can say what they were treated for and roughly when.

Speak to the adolescent directly for part of every visit, with the caregiver stepping out.
Introduce the treatment summary as their document, not the parent's.
Begin a plain-language explanation of the exposures that carry lifelong follow-up.

Ages 15 to 17 — build the skills

The survivor can book an appointment, list medications, and describe their surveillance schedule.

Run a short readiness check at each visit rather than a single hand-off assessment.
Confirm the treatment summary and surveillance plan are printable and in their possession.
Cover fertility, contraception, alcohol, and cardiovascular risk in a private conversation.
Name the age at which consent and record access transfer in your jurisdiction, before it happens.

Ages 18 to 21 — transfer, do not discharge

An identified adult clinician has accepted the survivor and has the exposure history.

Send a hand-off letter with cumulative anthracycline dose, radiation fields and doses, and the surveillance schedule.
Book the first adult appointment before the final pediatric visit ends.
Confirm insurance continuity and give the survivor a copy of everything sent.
Close the loop: a transfer without a confirmed first adult visit is a lapse waiting to happen.

Ages 22 to 39 — keep the thread

Surveillance continues through moves, job changes, and pregnancy.

Re-issue the one-page summary at every move or change of clinician.
Review cardiac risk before pregnancy in anyone with anthracycline or chest-radiation exposure.
Reassess neurocognitive accommodation needs at each educational or occupational transition.

What belongs in the hand-off letter

Diagnosis, age at diagnosis, and treatment dates.
Cumulative anthracycline dose expressed in doxorubicin equivalents.
Radiation fields with doses, including whether the heart, neck, or abdomen was in field.
Alkylator exposure with cyclophosphamide equivalent dose, plus platinum and bleomycin exposure.
Transplant and conditioning details, including revaccination status.
The resulting surveillance schedule with intervals and the guideline source for each.
Active late effects, current medications, and any accommodation needs.
Named contact for questions, and confirmation that the survivor holds an identical copy.

Questions clinicians ask about AYA transition

When should transition planning for an adolescent cancer survivor begin?

Around ages 12 to 14, well before transfer. Transition is a multi-year skill-building process, not the final pediatric appointment. By the mid-teens the survivor should be able to name their diagnosis, treatment exposures, and surveillance schedule.

What has to be in an AYA survivorship hand-off letter?

Diagnosis and dates, cumulative anthracycline dose in doxorubicin equivalents, radiation fields with doses, other significant exposures such as alkylators or platinum, the resulting surveillance schedule with intervals, and current issues. The survivor should hold a copy of the same document.

Who should receive an adult survivor of childhood cancer?

Either a dedicated adult survivorship or late-effects clinic, or a primary-care clinician supported by a written exposure-indexed schedule and a named specialist for questions. What matters is that the receiving clinician is identified and has accepted the survivor before the pediatric relationship ends.

Why do AYA survivors fall out of follow-up after transfer?

The common causes are a transfer with no confirmed first adult appointment, insurance change at age 18 to 26, relocation for school or work, and a survivor who cannot reproduce their own treatment history when asked. Each is addressable in advance.

Where to go next

Hand-off letter template

Printable transition and care-plan templates.

Surveillance schedules by exposure

Build the schedule the receiving clinician will follow.

The survivor-facing version

Share this with the AYA survivor preparing to transfer.

Back to the gap map

The full index of survivorship questions and their answers.

No login or chart access needed. Privacy questions are answered on the privacy FAQ.